[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer
These early results suggest the potential of [<sup>18</sup>F]FTT-PET to select patients for PARPi treatment and monitor in vivo pharmacodynamics after therapy start. Absence of association with HRD scores supports [<sup>18</sup>F]FTT uptake as a novel measure that may be leveraged as a biomarker. Further studies are warranted.
Authors
- Sophia R. O’Brien (ORCID: https://orcid.org/0000-0002-2685-101X)
- Austin R. Pantel (ORCID: https://orcid.org/0000-0001-8649-9970)
- Quy Cao (ORCID: https://orcid.org/0000-0002-6204-1305)
- Elizabeth S. McDonald (ORCID: https://orcid.org/0000-0002-7209-4216)
- Kara N. Maxwell (ORCID: https://orcid.org/0000-0001-8192-4202)
- Amy S. Clark (ORCID: https://orcid.org/0000-0002-3685-6535)
- Sarah B. Gitto (ORCID: https://orcid.org/0000-0001-6496-4528)
- Michael D. Farwell (ORCID: https://orcid.org/0000-0003-0650-4747)
- Daniel A. Pryma (ORCID: https://orcid.org/0000-0001-8978-4419)
- Fang Liu (ORCID: https://orcid.org/0000-0003-2922-4414)
- Payal Shah (ORCID: https://orcid.org/0009-0004-7225-1674)
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1038/s43856-025-00791-0
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- METAvivor